Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells

Experimental and Molecular Medicine

Volumn 46, Issue 2, 2014, Pages

  Lee, Sook Jeong ^a   Hwang, Sung Ook ^b   Noh, Eun Joo ^a,e   Kim, Dong Uk ^c   Nam, Miyoung ^a   Kim, Jong Hyeok ^d   Nam, Joo Hyun ^d   Hoe, Kwang Lae ^a  

^a Chungnam National University   (South Korea)

^b Inha University Hospital   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Asan Medical Center   (South Korea)

^e Korea Intellectual Property Office   (South Korea)

Author keywords

Bad; Cervical cancer cell; Doxorubicin; P53 acetylation; Vorinostat

Indexed keywords

CASPASE 3; DNA; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; PROTEIN P53; SMALL INTERFERING RNA; VORINOSTAT; ANTINEOPLASTIC AGENT; BAD PROTEIN, HUMAN; HYDROXAMIC ACID;

ACYLATION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSACTIVATION; UPREGULATION; UTERINE CERVIX CANCER; ACETYLATION; CELL SURVIVAL; CHROMATIN; GENETICS; HELA CELL LINE; METABOLISM; TRANSCRIPTION INITIATION; UTERINE CERVIX TUMOR;

ACETYLATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CELL SURVIVAL; CHROMATIN; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HELA CELLS; HUMANS; HYDROXAMIC ACIDS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84896883486     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.149     Document Type: Article

References (25)

1. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-468.
2. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009; 16: 3267-3285.
3. Welander CE, Homesley HD, Barrett RJ. Combined interferon alfa and doxorubicin in the treatment of advanced cervical cancer. Am J Obstet Gynecol 1991; 165: 284-290.
4. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26: 1351-1356.
5. Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 2012; 4: 1439-1460.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59: 225-249.
7. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55-F78.
8. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
9. Feng L, Lin T, Uranishi H, Gu W, Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 2005; 25: 5389-5395.
10. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
11. Jiang P, Du W, Heese K, Wu M. The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol Cell Biol 2006; 26: 9071-9082.
12. Jiang P, Du W, Wu M. p53 and Bad: remote strangers become close friends. Cell Res 2007; 17: 283-285.
13. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63: 7291-7300.
14. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004; 92: 223-237.
15. Zhao L, Au JL, Wientjes MG. Comparison of methods for evaluating drugdrug interaction. Front Biosci (Elite Ed) 2010; 2: 241-249.
16. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernandez G, Rodriguez A, Lopez-Rivas A et al. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002; 277: 10883-10892.
17. Koivusalo R, Hietanen S. The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status. Cancer Biol Ther 2004; 3: 1177-1183.
18. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291.
19. Simoes-Wust AP, Schurpf T, Hall J, Stahel RA, Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat 2002; 76: 157-166.
20. Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JM. Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat 2007; 102: 173-179.
21. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694.
22. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
23. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
24. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002; 4: 842-849.
25. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21: 6236-6245.